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(CAD), including those with a history of myo‑
cardial infarction cuts the risk of recurrent 
cardiovascular events and all ‑cause mortality 
IntroductIon Smoking is a major modifi‑
able cardiovascular risk factor.1‑3 Smoking ces‑
sation in patients with coronary artery disease 
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AbstrAct
Background Smoking cessation in patients with coronary artery disease (CAD) is related to decreased 
risk of cardiovascular events.
aims To evaluate factors related to persistent smoking in patients with established coronary artery disease.
methods Patients aged 80 years or younger and hospitalized for acute coronary syndrome or a myocardial 
revascularization procedure were interviewed 6 to 18 months after the recruiting event. Medical history, 
smoking behavior, and exposure to environmental smoke were assessed during the interview. Self­
­reported smoking status was validated by carbon monoxide in exhaled air measurement. Persistent 
smoking was defined as smoking at the time of interview among those who smoked during the month 
prior to the recruiting event.
results We analyzed the data of 1034 patients, including 764 (73.9%) who reported smoking at any 
time in the past and 296 (28.6%) who smoked within 1 month before the recruiting hospitalization. At the 
time of the interview, the overall smoking rate was 17.2%, whereas 54.7% of patients were persistent 
smokers. Secondhand smoke exposure and duration of smoking were associated with lower likelihood 
whereas older age, high socioeconomic status, cardiac rehabilitation following a cardiovascular event, 
and consultation with a cardiologist were associated with higher likelihood of smoking cessation.
conclusions Over half of all smokers hospitalized for CAD are still smoking 6 to 18 months after discharge. 
Older age, secondhand smoking, low socioeconomic status, lack of consultation with a cardiologist, and 
cardiac rehabilitation following hospitalization were related to persistent smoking. Our findings may help 
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from 18 to 80 years. Centrally trained research 
staff collected data using standardized meth‑
ods and the same instruments in all centers. 
Overall, 1236 patients were invited to partic‑
ipate in the study and their medical records 
were reviewed.
The survey participants were interviewed 6 
to 18 months after discharge from the hospi‑
tal. A patient’s personal medical history, life‑
style, and medications used were assessed 
using a standard questionnaire. The partici‑
pants’ education was assessed on the basis of 
the number of years of formal education com‑
pleted. Self ‑perceived income was based on 
the answers to the question: “In your opinion, 
your family income is: very low, low, interme‑
diate, high.” The following question was aimed 
at measuring loneliness: “Do you have some‑
body with whom you share your problems or 
happiness?” Height and weight were measured 
in a standing position without shoes and heavy 
outerwear using standard scales with a ver‑
tical ruler (SECA). The scales were calibrat‑
ed at the start of the survey. Body mass index 
(BMI) was calculated according to the follow‑
ing formula: BMI = weight [kg] / (height [m])2. 
Obesity was defined as BMI of 30 kg/m2 or 
greater. Blood pressure was measured twice in 
the right arm in a sitting position after 5 min‑
utes of rest at least. The average of the 2 read‑
ings was used in the present analysis. High 
blood pressure was defined as blood pressure of 
140/90 mm Hg or greater or 140/85 mm Hg or 
greater in patients with diabetes. A fasting ve‑
nous blood sample was taken to measure plas‑
ma lipid and creatinine levels. For the purpos‑
es of the present report, the results of analyses 
performed no later than 12 hours after blood 
collection were used. The level of LDL choles‑
terol was calculated according to the Friede‑
wald formula. A high cholesterol level was de‑
fined as LDL cholesterol of 1.8 mmol/l or great‑
er. Glomerular filtration rate was defined us‑
ing the Modification of Diet in Renal Disease 
formula. Patient psychosocial characteristics 
were assessed using the Hospital Anxiety and 
Depression Scale.11
Finally, we constructed a socioeconomic sta‑
tus (SES) summary score on the basis of vari‑
ous socioeconomic components. This score was 
the sum of the following subscores: education‑
al level (primary school completed or less, 0 
points; intermediate, 2; college / university, 
4), perceived income (very low = 0; low = 2; in‑
termediate = 4; high = 6), loneliness (yes = 0; 
no = 2), employment (yes, 2; no, 0), and being 
married (yes = 1; no = 0). Based on this summa‑
ry score, varying from 0 to 15, we subdivided 
our sample in 2 groups: patients at a “low SES 
level” had a summary score of 7 or less, and 
those having a “high SES level” had scores of 
8 or more.
substantially.4 However, only half of smokers 
with CAD in Europe are able to successfully quit 
smoking.5,6 The European guidelines on cardio‑
vascular prevention in clinical practice recom‑
mend a comprehensive approach to risk factor 
management in the secondary prevention of 
CAD.7 Optimal secondary prevention includes 
lifestyle modification, appropriate pharma‑
cotherapy, control of blood pressure and low‑
‑density lipoprotein (LDL) cholesterol and no 
exposure to tobacco in any form.1,7 Several re‑
cent surveys showed a considerable potential for 
further improvement of secondary prevention in 
European countries, including Poland.6,8 More‑
over, the available data suggest that the propor‑
tion of patients still smoking following a hos‑
pitalization due to CAD has not changed sub‑
stantially for over 20 years.9,10 Despite convinc‑
ing evidence, smoking cessation strategies have 
been poorly implemented.5,6
The POLASPIRE survey is the most recent 
survey in Poland designed to gauge the imple‑
mentation of the recently published guidelines 
for the secondary prevention of CAD by as‑
sessing control of main risk factors and pre‑
scription rates of cardioprotective medication 
in patients with established CAD.8 The aim of 
the present analysis was to investigate factors 
related to smoking cessation following hospi‑
talization due to CAD.
Methods The POLASPIRE study was a cross‑
‑sectional, multicenter survey carried out in 4 
regions: one in northern, one in central, and 2 
in the southern part of Poland in 2016 to 2017 
and was described in detail elsewhere.8 Briefly, 
in each region, at least one teaching and one mu‑
nicipal hospital took part in the survey. In total, 
14 departments of cardiology from 12 different 
hospitals participated. Seven departments were 
located in teaching hospitals and 7 in munici‑
pal hospitals. The inclusion criteria for the PO‑
LASPIRE survey were as follows: past hospital‑
ization for acute coronary syndrome or a myo‑
cardial revascularization procedure and be age 
whAt’s new?
Our results suggest that three ­quarters of patients with established coronary 
artery disease (CAD) are current or prior smokers and roughly 55% of those 
who smoked in the month prior to the recruiting event are persistent smokers. 
Overall, the smoking rate was 17% and thus did not differ significantly from 
surveys published 10 and 20 years ago. Approximately a quarter of all CAD 
patients and roughly half of all persistent smokers are exposed to environmental 
tobacco smoke. We found that more patients are exposed to environmental 
tobacco smoke at home than at work. Secondhand smoke exposure and duration 
of smoking were associated with lower likelihood of smoking cessation in our 
population, whereas in the case of older age, high socioeconomic status, cardiac 
rehabilitation following an cardiovascular event, and specialized cardiac care, 
this likelihood was higher.
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regression analysis was performed to assess fac‑
tors independently related to smoking during 
the postdischarge period. A 2‑tailed P value of 
less than 0.05 was regarded as indicating statis‑
tical significance. The statistics were calculated 
with the STATISTICA 13 software (TIBCO Soft‑
ware, Palo Alto, United States).
results Overall, 1034 patients participated in 
the survey and their data were analyzed, includ‑
ing 764 (73.9%) who reported having smoked 
at any time in the past and 296 (28.6%) who 
smoked within the month preceding the recruit‑
ment, whereas 270 (26.1%) participants report‑
ed they had never smoked. The characteristics 
of the study groups are presented in TABLE 1 (after 
exclusion of 16 cases who did not smoke within 
the month preceding the recruiting hospitaliza‑
tion and smoked at the time of follow ‑up inter‑
view). At the time of the interview, the smoking 
rate was 17.2% (16.4% of patients reported cur‑
rent smoking). Among those who were smokers 
within the month prior to the recruiting hospi‑
talization, 54.7% were smoking at the time of 
the interview. Smokers were younger than non‑
smoking patients and more often were hospital‑
ized for cardiovascular disease before the re‑
cruiting event. Persistent smokers participated 
in the cardiac rehabilitation program less often 
and less frequently consulted a cardiologist fol‑
lowing discharge from the hospital. They were 
also more likely to have high LDL cholesterol 
levels. On the other hand, there was a trend for 
more prevalent obesity among quitters (TABLE 1). 
Among those who were not current smokers be‑
fore the recruiting event, 16 (2.2%) were smokers 
at the time of the interview. This group consisted 
of 12 men and 4 women, the mean (SD) age was 
Assessment of smoking behavior Infor‑
mation on smoking behavior was collected us‑
ing a standard interview questionnaire. The pa‑
tients were asked if they had ever smoked and 
if they were smoking during the month prior 
to hospital admission for the recruiting event. 
The study participants were also asked about 
the mean number of cigarettes they smoked, 
duration of their smoking habit, any attempts 
they had made to quit smoking, and secondhand 
smoke exposure. Smoking at the time of inter‑
view was defined as self ‑reported smoking veri‑
fied by the concentration of breath carbon mon‑
oxide using a smoker analyzer (Bedfont Scientif‑
ic, Model Micro+, Bedfont Scientific, Kent, Unit‑
ed Kingdom). Breath carbon monoxide exceed‑
ing 10 ppm was considered to be an indication 
of current smoking. Pre ‑event smoking was de‑
fined as being current smoker within the month 
prior to the recruiting event. Persistent smoking 
was defined as smoking at the time of interview 
among those who had smoked during the month 
prior to the recruiting event. The survey’s proto‑
col was approved by the institutional Bioethics 
Committees. Every patient signed an informed 
consent form.
statistical analysis Categorical variables were 
reported as percentages and continuous vari‑
ables as means (SD) or medians (interquartile 
ranges [IQRs]). The χ2 or the Fisher exact test was 
applied to all the categorical variables. The Sha‑
piro–Wilk test was used to assess the normality. 
Normally distributed continuous variables were 
compared using the t test. Variables without 
normal distributions were evaluated by means 
of the Mann–Whitney test. The Bonferroni cor‑
rection was used to account for the multiple 
comparisons. Stepwise, multivariable logistic 
Table 1 Characteristics of the study groups (continued on the next page)
Characteristics Not smoking before the 
recruiting event, not 
smoking after 
the recruiting event 
(n = 722)
P value Smoking before the 
recruiting event, not 
smoking after 
the recruiting event 
(n = 134)
P value Smoking before the 
recruiting event, 
smoking after 
the recruiting event 
(n = 162)
Age, y 68 (62.8–73.7) <0.001 63.1 (59–69.1) 0.014 61.5 (55.9–66)
Sex Male 503 (69.7) 0.18 101 (75.4) 0.72 125 (77.2)
Female 219 (30.3) 33 (24.6) 37 (22.8)
Marital status Married 534 (74) 0.24 95 (70.9) 0.88 115 (71.1)
Divorced / separated 47 (6.5) 15 (11.2) 22 (13.6)
Widowed 115 (15.9) 18 (13.4) 18 (11.1)
Never married 26 (3.6) 5 (3.7) 6 (3.7)
Living alone 114 (15.8) 0.63 23 (17.2) 0.49 25 (15.4)
Loneliness 22 (3) 0.34 6 (4.5) 0.95 7 (4.3)
Duration of education, y 12 (10–15) 0.8 12 (11–14) 0.21 12 (11–13)
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The characteristics of smoking behavior are 
presented in TABLE 2. Successful quitters reported 
a shorter duration of smoking and less frequent 
exposure to second ‑hand smoke at work and 
at home. Overall, 23.7% of participants were ex‑
posed to environmental tobacco smoke, includ‑
ing 6.8% exposed at work and 16.6% exposed 
at home. Among those who were professionally 
60.9 (8.6) years (P <0.01) compared with the rest 
of nonsmokers prior to the recruiting hospital‑
ization), and 13 (81.3%) were hospitalized for 
cardiovascular disease prior to the recruitment 
event (P = 0.04). The majority of them were for‑
mer smokers and only one participant report‑
ed that he had never smoked before the recruit‑
ment event but started to smoke after discharge.
Table 1 Characteristics of the study groups (continued from the previous page)
Characteristics Not smoking before the 
recruiting event, not 
smoking after 
the recruiting event 
(n = 722)
P value Smoking before the 
recruiting event, not 
smoking after 
the recruiting event 
(n = 134)
P value Smoking before the 
recruiting event, 
smoking after 
the recruiting event 
(n = 162)
Household incomea High 35 (4.9) 0.56 7 (5.2) 0.94 6 (3.7)
Medium 473 (65.5) 81 (60.4) 98 (60.5)
Low 185 (25.6) 38 (28.4) 48 (29.6)
Very low 29 (4) 8 (6) 10 (6.4)
Employed 196 (27.1) 0.006 52 (38.8) 0.82 65 (40.1)
High socioeconomic status 267 (37) 0.05 62 (46.3) 0.1 59 (36.4)
Recruiting event Myocardial 
infarction
235 (32.5) <0.001 76 (56.7) 0.25 75 (46.3)
Unstable angina 178 (24.7) 18 (13.4) 21 (13)
PCI 275 (38.1) 37 (27.6) 60 (37)
CABG 34 (4.7) 3 (2.2) 6 (3.7)
Hospitalization in teaching hospital 595 (82.4) 0.59 113 (84.3) 0.82 135 (83.3)
Previous hospitalization for cardiovascular 
diseaseb
403 (55.8) <0.001 42 (31.3) 0.009 75 (46.3)
Participation in a cardiac rehabilitation 
program following discharge
197 (27.3) 0.001 55 (41) 0.004 41 (25.3)
Physician specialty Cardiologist 637 (88.2) 0.68 117 (87.3) 0.006 120 (74.1)
General practitioner 622 (86.1) 0.37 111 (82.8) 0.37 141 (87)
Diabetologist 76 (10.5) 0.76 15 (11.2) 0.94 18 (11.1)
Other physician 22 (3) 0.36 2 (1.5) 0.25 6 (3.7)
No physician 6 (0.8) 0.29 0 0.37 1 (0.6)
Obesity 310 (42.9) 0.48 62 (46.3) 0.05 57 (35.2)
Diabetes 277 (38.4) 0.03 38 (28.4) 0.9 47 (29)
High blood pressurec 324 (44.9) 0.19 52 (38.9) 0.4 55 (33.9)
High LDL cholesterold 450 (62.3) 0.09 73 (54.5) 0.004 114 (70.4)
GFR <60 ml/kg/1.73 m2 153 (21.2) 0.009 15 (11.2) 0.58 15 (9.3)
Depression scoree 5 (3–8) 0.54 5 (2–8) 0.72 6 (2–8)
Anxiety scoree 6 (3–8) 0.93 5 (3–8) 0.61 6 (3–8)
Data are presented as number (percentage) of patients or median (interquartile range).
a Based on the patient’s report
b  Hospitalization before the recruiting event due to: coronary artery bypass grafting, percutaneous coronary intervention, acute coronary syndrome, chronic coronary 
syndrome, heart failure, stroke, or peripheral artery disease
c Blood pressure ≥140/90 mm Hg or ≥140/85 mm Hg in patients with diabetes
d Low ­density lipoprotein cholesterol ≥1.8 mmol/l
e Based on the Hospital Anxiety and Depression Scale
Abbreviations: CABG, coronary artery bypass grafting; GFR, glomerular filtration rate; LDL, low ‑density lipoprotein; PCI, percutaneous coronary intervention
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duration of smoking were associated with lower 
likelihood whereas older age, high socioeconomic 
status, cardiac rehabilitation following cardiovas‑
cular event, and consultation with a cardiologist 
were associated with a higher likelihood of smoking 
cessation following the recruiting hospitalization.
dIscussIon The present results suggest that 
roughly three ‑quarters of patients with estab‑
lished CAD are current or prior smokers and 
55% of those smoking in the pre ‑event peri‑
od were persistent smokers. There is strong 
active, 22% were exposed to environmental to‑
bacco smoke at work. The smoking cessation 
therapies used by the pre ‑event smokers are pre‑
sented in TABLE 3. Smoking cessation was only at‑
tempted by 64.2% of persistent smokers whereas 
76.5% tried to reduce the number of cigarettes 
they smoked. At the time of the interview, none 
of the smokers used nicotine replacement thera‑
py, bupropion or varenicline, and only a few pa‑
tients tried these therapies during the period 
from discharge to the follow ‑up examination.
The results of multivariable analyses are pre‑
sented in TABLE 4. Secondhand smoke exposure and 
Table 2 Characteristics of the smoking behavior
Characteristics Not smoking before 
the recruiting event, 
not smoking after 
the recruiting event 
(n = 722)
P value Smoking before 
the recruiting event, 
not smoking after 
the recruiting event 
(n = 134)
P value Smoking before 
the recruiting event, 
smoking after 
the recruiting event 
(n = 162)
Duration of smoking, y 20 (15–35)a <0.001 35 (30–45) 0.11 40 (30–45)
Number of smoked cigarettes daily in 
the postdischarge period
– – – – 10 (4–15)
Planning to stop smoking – – – – 79 (48.8)
E ­cigarettes use 0 >0.99 0 0.07 4 (2.5)
Secondhand smoking At work 30 (4.2) 0.83 6 (4.5) <0.001 34 (21)
At home 84 (11.6) 0.04 24 (17.9) <0.001 59 (36.4)
Other 
places
19 (2.6) <0.001 19 (14.2) 0.89 22 (13.6)
Any secondhand smoking 117 (16.2) <0.001 41 (30.6) <0.001 84 (51.9)
Data are presented as number (percentage) of patients or median (interquartile range).
a Among participants who reported smoking at any time (n = 452)
Table 3 Smoking cessation therapies
Therapy Smoking before 
the recruiting event, 
smoking after the recruiting 
event (n = 162)
Smoking before 
the recruiting event, not 
smoking after the recruiting 
event (n = 134)
P value Total 
(n = 296)
Trying to stop smoking since recruiting event 104 (64.2) 134 (100) <0.001 238 (80.4)
Trying to reduce number of smoked cigarettes since 
the recruiting event
124 (76.5) 9 (6.7) <0.001 133 (44.9)
Smoking cessation clinic 0 1 (0.7) 0.27 1 (0.3)
Nicotine replacement 
therapy
Since recruiting event 9 (5.6) 1 (0.7) 0.02 10 (3.4)
At the time of the follow ­up 
examination
0 0 – 0
Bupropion Since recruiting event 0 0 – 0
At the time of the follow ­up 
examination
0 0 – 0
Varenicline Since recruiting event 1 (0.6) 1 (0.7) 0.89 2 (0.7)
At the time of the follow ­up 
examination
0 0 – 0
Data are presented as number (percentage) of patients.
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European countries, and a decline in average 
smoking prevalence in many European coun‑
tries, including Poland, postevent cessation 
rates in patients with CAD remain at the lev‑
el of 50%.5,16
In line with previous reports, increasing age, 
cardiac rehabilitation following a cardiovascular 
event, absence of passive smoking, and high so‑
cioeconomic status were associated with smok‑
ing cessation in our population.5,17,18 On the other 
hand, we did not find evidence that depression 
and anxiety are related to persistent smoking. 
Previous studies reported conflicting results re‑
garding the relation between these factors and 
persistent smoking.5,19 ‑21
Secondhand smoke exposure increases car‑
diovascular risk and decreases the probability 
of smoking cessation in various settings.5,17, 20, 2 2 
We found that about a quarter of patients fol‑
lowing CAD hospitalization are exposed to 
environmental tobacco smoke. Importantly, 
half of all persistent smokers were exposed 
to second ‑hand smoke. In general, our re‑
sults show that more patients are exposed to 
environmental tobacco smoke at home than 
at work. However, among professionally ac‑
tive patients, a comparable proportion are ex‑
posed to environmental tobacco smoke at work 
and at home.
scientific evidence that the long ‑term surviv‑
al of patients with CAD may be improved by 
providing optimal secondary prevention in‑
cluding smoking cessation therapies.7 The re‑
sults of the EUROASPIRE surveys showed that 
smoking rates among patients with established 
CAD have not changed significantly in Europe 
over the last 2 decades (21% in 1999 to 2000 vs 
20% in 2006 to 2007 vs 18% in 2012 to 2013).9 
There is solid scientific evidence for the effec‑
tiveness of various types of nicotine replace‑
ment therapy, bupropion, cytisine, and vare‑
nicline.12‑15 Smoking cessation is the most cost‑
‑effective strategy in cardiovascular preven‑
tion.7 Despite convincing evidence, smoking 
cessation strategies were poorly implemented in 
the participants of our survey. Indeed, the low 
prescription rates of smoking cessation thera‑
pies may be one of the major determinants of 
the high rate of persistent smoking. Nicotine re‑
placement therapy, varenicline, and bupropion 
were used significantly less often in the POLAS‑
PIRE as compared with the EUROASPIRE sur‑
vey.5 The participation rate in smoking cessation 
programs was also extremely low in the study 
group. Indeed, despite the increase in the num‑
ber of available smoking cessation strategies, 
educational campaigns, laws restricting smok‑
ing in public spaces in an increasing number of 
Table 4 Results of a multivariable analysis with smoking and persistent smoking as dependent variables
Variable Odds ratio (95% CI) P value Wald χ2 statistics
Persistent smoking (n = 296)
Age, per 10 years 0.43 (0.29–0.64) <0.001 17.88
Duration of smoking, per ten years 1.53 (1.20–1.96) <0.001 11.59
Secondhand smoking 2.27 (1.35–3.84) 0.002 9.49
Consultation with a cardiologist 0.41 (0.21–0.82) 0.01 6.48
Cardiac rehabilitation following discharge 0.51 (0.29–0.89) 0.02 5.61
High socioeconomic status 0.54 (0.31–0.93) 0.03 4.98
Previous hospitalization due to cardiovascular 
diseasea
1.73 (1.01–2.97) 0.04 4.04
Smoking (n = 1034)
Smoking before recruiting event 25.97 (13.81–48.85) <0.001 102.32
Age, per 10 years 0.43 (0.31–0.59) <0.001 27.12
Duration of smoking, per 10 years 1.55 (1.27–1.89) <0.001 18.76
Consultation with a cardiologist 0.42 (0.23–0.77) 0.005 8.07
Previous hospitalization due to cardiovascular 
diseasea
1.87 (1.15–3.04) 0.01 6.4
Secondhand smoking 1.81 (1.14–2.89) 0.01 6.23
High socioeconomic status 0.57 (0.35–0.92) 0.02 5.19
Cardiac rehabilitation following discharge 0.60 (0.36–0.99) 0.047 3.94
a Hospitalization before the recruiting event due to: coronary artery bypass grafting, percutaneous coronary intervention, acute 
coronary syndrome, chronic coronary syndrome, heart failure, stroke, or peripheral artery disease
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We found that specialized cardiology care 
was independently related to lower probability 
of smoking both when we analyzed the study 
group as a whole as well as when we limited 
the analysis to pre ‑event smokers. There are 
at least 3 possible explanations for this finding. 
Firstly, patients consulted and not consulted by 
a cardiologist may differ with respect to a num‑
ber of unrecognized features, including higher 
compliance with the physicians’ recommenda‑
tions. Secondly, cardiologists may devote more 
time to controlling major cardiovascular risk fac‑
tors compared with general practitioners. Final‑
ly, as a specialist has usually greater authority 
than a general practitioner, this might partial‑
ly explain the finding. The relationship between 
a consultation with a cardiologist and smoking 
prevalence in patients with CAD could help ex‑
plain the lower risk of death among postinfarc‑
tion patients consulted by a cardiologist.2 3
Our results suggest that smoking rates in pa‑
tients with established CAD might be reduced by 
lowering environmental tobacco smoking and in‑
creasing access to cardiac rehabilitation and car‑
diac care. A program of managed care for myo‑
cardial infarction survivors recently launched in 
Poland has particularly addressed both factors.24
limitations Apart from the cross ‑sectional 
design which does not allow to address causali‑
ty, the present analysis has several limitations. 
Firstly, we were unable to assess the relation 
between smoking status and the risk of cardio‑
vascular complications.8 Secondly, participants 
of the present study were not representative of 
all CAD patients. Participants were limited to 
those who had experienced an acute CAD event 
or had undergone a revascularization procedure. 
Thirdly, we only included patients aged 80 years 
or younger. Therefore, our results do not refer di‑
rectly to older patients. However, an important 
advantage of our analysis is that our results are 
not based solely on abstracted medical record 
data but took into account face ‑to ‑face inter‑
views and examinations using the same proto‑
col and standardized methods and instruments. 
Therefore, to our best knowledge, presented re‑
sults provide the most current and reliable in‑
formation on smoking management for second‑
ary prevention of CAD.
conclusions Over half of all smokers hospi‑
talized due to CAD smoke 6 to 18 months af‑
ter discharge. Secondhand smoke exposure and 
duration of smoking were associated with low‑
er likelihood, whereas older age, high socioeco‑
nomic status, cardiac rehabilitation following 
cardiovascular event, and specialized cardiac 
care were associated with higher likelihood of 
smoking cessation. Our findings may be useful 
for developing strategies to assist smoking ces‑
sation in patients with CAD.
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